[Vascular pathology secondary to administration of estroprogestogens].
D000328:Adult; D001778:Blood Coagulation Disorders / Q000139:chemically induced*; D001780:Blood Coagulation Tests; D002715:Chlormadinone Acetate / Q000009:adverse effects; D003276:Contraceptives, Oral / Q000009:adverse effects*; D004967:Estrogens / Q000009:adverse effects*; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D006801:Humans; D008234:Lynestrenol / Q000009:adverse effects; D008535:Megestrol / Q000009:adverse effects; D008656:Mestranol / Q000009:adverse effects; D009640:Norethindrone / Q000009:adverse effects; D011278:Pregnanes / Q000009:adverse effects; D011372:Progestins / Q000009:adverse effects*; D013923:Thromboembolism / Q000139:chemically induced*; D013927:Thrombosis / Q000139:chemically induced*; D014652:Vascular Diseases / Q000139:chemically induced*
D003276:Contraceptives, Oral; D004967:Estrogens; D011278:Pregnanes; D011372:Progestins; D002715:Chlormadinone Acetate; D004997:Ethinyl Estradiol; D008656:Mestranol; D008535:Megestrol; D008234:Lynestrenol; D009640:Norethindrone
Patologia vasculară secundară administrării de estropregestative.